Stockscreener 앱 받기
62.90
1.06%
0.66
시간 외 거래:
64.39
1.49
+2.37%
전일 마감가:
$62.24
열려 있는:
$62.06
하루 거래량:
1.20M
Relative Volume:
0.83
시가총액:
$6.59B
수익:
$628.56M
순이익/손실:
$141.82M
주가수익비율:
49.92
EPS:
1.26
순현금흐름:
$142.60M
1주 성능:
-6.72%
1개월 성능:
+7.23%
6개월 성능:
+28.08%
1년 성능:
+174.07%
1일 변동 폭
$61.75
$64.26
1주일 범위
$61.75
$70.37
52주 변동 폭
$20.84
$117.33
코르셉트 테라퓨틱스 Stock (CORT) Company Profile
명칭
Corcept Therapeutics Inc
전화
650.688.8803
주소
101 REDWOOD SHORES PARKWAY, REDWOOD CITY
CORT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CORT
Corcept Therapeutics Inc
|
62.90 | 6.59B | 628.56M | 141.82M | 142.60M | 1.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.52 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.49 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
595.70 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
232.75 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
229.22 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
코르셉트 테라퓨틱스 Stock (CORT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-11-06 | 업그레이드 | Truist | Hold → Buy |
| 2023-04-11 | 개시 | SVB Securities | Market Perform |
| 2023-04-04 | 개시 | Piper Sandler | Overweight |
| 2023-02-15 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-08-01 | 다운그레이드 | Truist | Buy → Hold |
| 2022-07-27 | 업그레이드 | Jefferies | Hold → Buy |
| 2022-06-27 | 재개 | Canaccord Genuity | Buy |
| 2022-02-02 | 개시 | Canaccord Genuity | Buy |
| 2022-01-28 | 개시 | Truist | Buy |
| 2020-08-05 | 다운그레이드 | Jefferies | Buy → Hold |
| 2019-09-24 | 개시 | Jefferies | Buy |
| 2019-09-06 | 개시 | H.C. Wainwright | Buy |
| 2019-02-04 | 다운그레이드 | B. Riley FBR | Buy → Neutral |
| 2018-08-10 | 재확인 | Stifel | Hold |
| 2018-05-31 | 다운그레이드 | Stifel | Buy → Hold |
| 2018-03-09 | 개시 | B. Riley FBR, Inc. | Buy |
| 2017-08-31 | 개시 | Stifel | Buy |
| 2017-02-02 | 개시 | Ladenburg Thalmann | Buy |
| 2015-04-21 | 개시 | FBR Capital | Outperform |
| 2014-01-13 | 다운그레이드 | Stifel | Buy → Hold |
| 2013-08-09 | 다운그레이드 | Janney | Buy → Neutral |
| 2013-08-09 | 다운그레이드 | Ladenburg Thalmann | Buy → Neutral |
| 2012-02-21 | 재확인 | JMP Securities | Mkt Outperform |
| 2010-01-06 | 업그레이드 | Ladenburg Thalmann | Neutral → Buy |
| 2008-07-17 | 개시 | Rodman & Renshaw | Mkt Outperform |
| 2007-06-21 | 업그레이드 | Punk, Ziegel & Co | Mkt Perform → Accumulate |
모두보기
코르셉트 테라퓨틱스 주식(CORT)의 최신 뉴스
Diabetes Care Publishes Results From Prevalence Phase Of Corcept's CATALYST Trial In People With Difficult-To-Control Type 2 Diabetes | CORT Stock News - GuruFocus
Diabetes Care Publishes Results From Prevalence Phase Of Corcept'S CATALYST Trial In People With Difficult-To-Control Type 2 Diabetes - marketscreener.com
Landmark 1,000-Patient Diabetes Study Reveals Surprising Link to Cushing's Syndrome in Treatment-Resistant Cases - Stock Titan
SoundHound AI, Domo, Plug Power, Corcept, and 8x8 Shares Are Falling, What You Need To Know - Barchart.com
$1000 Invested In Corcept Therapeutics 20 Years Ago Would Be Worth This Much Today - Benzinga
It's Still Early For Corcept: With Multiple Growth Opportunities Ahead, It's No Longer Just A One Drug Wonder - Seeking Alpha
Corcept therapeutics director Daniel Swisher sells stock for $154,484 By Investing.com - Investing.com Canada
Corcept therapeutics director Daniel Swisher sells stock for $154,484 - Investing.com
Corcept Therapeutics (NasdaqCM:CORT) Rises 36% in Last Quarter - Yahoo
Corcept Initiates Trial Of Relacorilant Plus NAB-Paclitaxel And Bevacizumab - MarketScreener
Corcept Initiates Trial of Relacorilant Plus Nab-Paclitaxel and Bevacizumab in Patients With Platinum-Resistant Ovarian Cancer - Business Wire
Breakthrough Ovarian Cancer Trial Combines Three Powerful Treatments in Phase 2 Study - Stock Titan
How Some Mid Cap Stocks Outshone The S&P 400's Dramatic Drop Last Week (Mar 31-Apr 4) - Benzinga
Corcept Therapeutics (NASDAQ:CORT) Stock Price Expected to Rise, Piper Sandler Analyst Says - Defense World
Corcept Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:CORT - Benzinga
Commonwealth Equity Services LLC Has $700,000 Position in Corcept Therapeutics Incorporated (NASDAQ:CORT) - Defense World
What is HC Wainwright’s Estimate for CORT FY2026 Earnings? - Defense World
Corcept therapeutics officer sells $20.2 million in stock By Investing.com - Investing.com Australia
Piper Sandler lifts Corcept stock target to $131 post-study By Investing.com - Investing.com UK
Corcept Therapeutics’ chief development officer sells $77,639 in stock By Investing.com - Investing.com India
Corcept therapeutics CEO Joseph Belanoff sells $3.37 million in shares By Investing.com - Investing.com Canada
Corcept therapeutics CEO Joseph Belanoff sells $3.37 million in shares - Investing.com Australia
Corcept therapeutics president sells shares worth $10.1 million By Investing.com - Investing.com Canada
Corcept Therapeutics’ chief development officer sells $77,639 in stock - Investing.com
Corcept therapeutics president sells shares worth $10.1 million - Investing.com
Corcept therapeutics officer sells $20.2 million in stock - Investing.com
Corcept Therapeutics Stock (CORT) Rockets Up 100% After Groundbreaking Cancer Trial Success - markets.businessinsider.com
Does Corcept (CORT) Have the Potential to Rally 28.63% as Wall Street Analysts Expect? - Yahoo Finance
Corient Private Wealth LLC Purchases New Holdings in Corcept Therapeutics Incorporated (NASDAQ:CORT) - Defense World
Corcept Therapeutics (NASDAQ:CORT) Given New $142.00 Price Target at Canaccord Genuity Group - Defense World
Corcept's ovarian cancer drug meets main goal in late-stage study, shares jump - MSN
Corcept Therapeutics stock target raised to $150 by H.C. Wainwright - Investing.com Canada
Corcept Therapeutics (CORT) Stock Surges Following Positive Tria - GuruFocus
Corcept Therapeutics (CORT) Surges 109% Following Positive Trial Results - GuruFocus
U.S. Markets Ended Tuesday Mixed As monday.com Led, Corcept Therapeutics Lagged - Barron's
Yum Brands (YUM) Seeks New CEO as Corcept (CORT) and Hut 8 (HUT) Shares Climb - GuruFocus
Corcept Therapeutics Unusual Options Activity For April 01 - Benzinga
Daily Digest: State Farm's newest rate hike request; Stock soars on cancer results - The Business Journals
CORT Shares Rise as Relacorilant Combo Meets Ovarian Cancer Study Goal - TradingView
Corcept's relacorilant trial in patients with platinum-resistant ovarian cancer meets primary endpoint - Pharmafile
Corcept (CORT) Stock Jumps 109.1%: Will It Continue to Soar? - Nasdaq
Truist Securities lifts Corcept Therapeutics target to $150 - Investing.com
Here's Why Momentum in Corcept (CORT) Should Keep going - Yahoo Finance
Corcept Therapeutics: The ROSELLA Trial Presents A Major Win For The Company - Seeking Alpha
Why Corcept Therapeutics Incorporated (CORT) Went Up On Monday? - Yahoo
Corcept Therapeutics Reaches Analyst Target Price - Nasdaq
Corcept Therapeutics Shares Surge 109% to $114.22 on Phase 3 Trial Breakthrough - TradingPedia
Corcept’s Phase III trial of ovarian cancer therapy shows PFS improvement - Yahoo Finance
HC Wainwright Issues Positive Forecast for Corcept Therapeutics (NASDAQ:CORT) Stock Price - Defense World
AIG, Corcept Therapeutics, Dow - TradingView
Truist Financial Issues Positive Forecast for Corcept Therapeutics (NASDAQ:CORT) Stock Price - Defense World
코르셉트 테라퓨틱스 (CORT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.15%
4.32%
자본화:
|
볼륨(24시간):